Adrenal Lymphocytic Infiltration and Adrenocortical Tumors in a Patient with 21-Hydroxylase Deficiency

To the Editor: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial (Nov.5 issue) 1 is the third study, after the Scandinavian Simvastatin Survival Study 2 and the Cholesterol and Recurrent Events study, 3 on the use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors for secondary prevention of coronary disease.The positive results of this trial are as marginal as those of the studies that preceded it.The authors calculated relatively high values for risk re-*Trials whose authors originally acknowledged not having obtained IRB approval or informed consent are included with trials whose authors did not originally disclose information about these issues.For comparisons of the failure to disclose information on one or both issues, the percentages of authors who failed to report on both must be added to the percentages of authors who failed to report on one.